1. Home
  2. OBK vs ANAB Comparison

OBK vs ANAB Comparison

Compare OBK & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Bancorp Inc.

OBK

Origin Bancorp Inc.

HOLD

Current Price

$45.31

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$62.95

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OBK
ANAB
Founded
1912
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
OBK
ANAB
Price
$45.31
$62.95
Analyst Decision
Strong Buy
Buy
Analyst Count
6
12
Target Price
$46.67
$71.67
AVG Volume (30 Days)
158.4K
616.1K
Earning Date
04-22-2026
05-08-2026
Dividend Yield
2.13%
N/A
EPS Growth
N/A
91.02
EPS
0.89
N/A
Revenue
N/A
$234,603,000.00
Revenue This Year
$26.43
N/A
Revenue Next Year
$5.79
$52.14
P/E Ratio
$51.83
N/A
Revenue Growth
N/A
157.01
52 Week Low
$32.13
$17.11
52 Week High
$48.12
$73.30

Technical Indicators

Market Signals
Indicator
OBK
ANAB
Relative Strength Index (RSI) 47.76 48.23
Support Level $42.75 $53.46
Resistance Level $46.02 $70.26
Average True Range (ATR) 1.13 4.70
MACD -0.31 -0.49
Stochastic Oscillator 8.17 35.15

Price Performance

Historical Comparison
OBK
ANAB

About OBK Origin Bancorp Inc.

Origin Bancorp Inc is a financial holding company that provides personalized, relationship banking to businesses, municipalities, and personal clients in the communities it serves. The company offers a broad range of financial services and operates more than 56 locations in Dallas/Fort Worth, East Texas, Houston, North Louisiana, Mississippi, South Alabama, and the Florida Panhandle. It also provides insurance agency products and services through its wholly owned insurance agency subsidiary. The company operates in one business segment, community banking, and is mainly engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: